Search Results - "ELLIS, Catherine E"

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib by Press, Michael F, Ellis, Catherine E, Gagnon, Robert C, Grob, Tobias J, Buyse, Marc, Villalobos, Ivonne, Liang, Zhiyong, Wu, Shafei, Bang, Yung-Jue, Qin, Shu-Kui, Chung, Hyun Cheol, Xu, Jianming, Park, Joon Oh, Jeziorski, Krzysztof, Afenjar, Karen, Ma, Yanling, Estrada, Monica C, Robinson, Douglas M, Scherer, Stefan J, Sauter, Guido, Hecht, J Randolph, Slamon, Dennis J

“…HER2/ERBB2 status is used to select patients for HER2-targeted therapy. HER2/ERBB2 amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas…”
Get full text

Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 by Kumar, Rakesh, Blakemore, Stephen J, Ellis, Catherine E, Petricoin, 3rd, Emanuel F, Pratt, Dexter, Macoritto, Michael, Matthews, Andrea L, Loureiro, Joseph J, Elliston, Keith

“…Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or…”
Get full text

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial by Salgado, Roberto, Denkert, Carsten, Campbell, Christine, Savas, Peter, Nuciforo, Paolo, Nucifero, Paolo, Aura, Claudia, de Azambuja, Evandro, Eidtmann, Holger, Ellis, Catherine E, Baselga, Jose, Piccart-Gebhart, Martine J, Michiels, Stefan, Bradbury, Ian, Sotiriou, Christos, Loi, Sherene

“…The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early…”
Get more information

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study by Iwata, Hiroji, Fujii, Hirofumi, Masuda, Norikazu, Mukai, Hirofumi, Nishimura, Yuichiro, Katsura, Koichi, Ellis, Catherine E., Gagnon, Robert C., Nakamura, Seigo

“…Background The results from a phase III trial conducted outside of Japan demonstrated a significant improvement in time to progression (TTP) when lapatinib was…”
Get full text

A proposed staging system for amyotrophic lateral sclerosis by Roche, Jose C, Rojas-Garcia, Ricardo, Scott, Kirsten M, Scotton, William, Ellis, Catherine E, Burman, Rachel, Wijesekera, Lokesh, Turner, Martin R, Leigh, P Nigel, Shaw, Christopher E, Al-Chalabi, Ammar

“…Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, with a median survival of 2-3…”
Get full text

The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison by Martin, Sarah, Trevor-Jones, Emma, Khan, Sabyha, Shaw, Keelan, Marchment, Deepti, Kulka, Anna, Ellis, Catherine E, Burman, Rachel, Turner, Martin R., Carroll, Liam, Mursaleen, Leah, Leigh, P. Nigel, Shaw, Christopher E., Pearce, Neil, Stahl, Daniel, Al-Chalabi, Ammar

“…Background: Care for people with amyotrophic lateral sclerosis (ALS) has altered at King's College Hospital over the last 20 years. The clinic has been a…”
Get full text

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab) by Ho, Diep, Huang, Jessica, Chapman, Judith-Anne W., Leitzel, Kim, Ali, Suhail M., Shepherd, Lois, Parulekar, Wendy R., Ellis, Catherine E., Crescnzo, Rocco J., Zhu, Liting, Virk, Shakeel, Nomikos, Dora, Aparicio, Samuel, Gelmon, Karen A., Carney, Walter P., Lipton, Allan

“…Background The lapatinib–taxane combination led to shorter PFS than trastuzumab–taxane in HER2+ metastatic breast cancer. We investigated the prognostic and…”
Get full text

The risk to relatives of patients with sporadic amyotrophic lateral sclerosis by Hanby, Martha F., Scott, Kirsten M., Scotton, William, Wijesekera, Lokesh, Mole, Thomas, Ellis, Catherine E., Nigel Leigh, P., Shaw, Christopher E., Al-Chalabi, Ammar

“…Amyotrophic lateral sclerosis is a neurodegenerative disease of motor neurons with a median survival of 2 years. Most patients have no family history of…”
Get full text

A proposed staging system for amyotrophic lateral sclerosis by ROCHE, Jose C, ROJAS-GARCIA, Ricardo, AL-CHALABI, Ammar, SCOTT, Kirsten M, SCOTTON, William, ELLIS, Catherine E, BURMAN, Rachel, WIJESEKERA, Lokesh, TURNER, Martin R, LEIGH, P. Nigel, SHAW, Christopher E

Get full text

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies by Anderson, Larry D., Cavet, James, Cohen, Adam D., Degenhardt, Yan Y., Ellis, Catherine E., Germaschewski, Fiona, Lendvai, Nikoletta, Libby, Edward, Opalinska, Joanna, Popat, Rakesh, Pouliquen, Isabelle, Richardson, Paul G., Stockerl-Goldstein, Keith E., Sutherland, Heather J., Trudel, Suzanne, Voorhees, Peter M., Wetherington, Jeffrey

“…Background: Expression of B cell maturation antigen (BCMA), a cell surface receptor belonging to the tumor necrosis factor receptor superfamily, is restricted…”
Get full text

Abdominal Injury-Football: 73 by Ellis, Catherine E., Seifert, Michael A.

Get full text

Abdominal Injury-Football: 73 by Ellis, Catherine E., Seifert, Michael A.

Get full text

erratum: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 by Ames, Robert S, Sarau, Henry M, Chambers, Johathan K, Willette, Robert N, Aiyar, Nambi V, Romanic, Anne M, Louden, Calvert S, Foley, James J, Sauermelch, Charles F, Coatney, Robert W, Ao, Zhaohui, Disa, Jyoti, Holmes, Stephen D, Stadel, Jeffrey M, Martin, John D, Liu, Wu-Schyong, Glover, George I, Wilson, Shelagh, McNulty, Dean E, Ellis, Catherine E, Elshourbagy, Nabil A, Shabon, Usman, Trill, John J, Hay, Douglas W. P, Ohlstein, Eliot H, Bergsma, Derk J, Douglas, Stephen A

Get full text

Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719 by Thomas, David R., Gittins, Susan A., Collin, Lissa L., Middlemiss, Derek N., Riley, Graham, Hagan, Jim, Gloger, Israel, Ellis, Catherine E., Forbes, Ian T., Brown, Anthony M.

“…1 The functional profile of the long form of the human cloned 5‐HT7 receptor (designated h5‐HT7(a)) was investigated using a number of 5‐HT receptor agonists…”
Get full text

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation by Cohen, Adam D., Popat, Rakesh, Trudel, Suzanne, Richardson, Paul G, Libby, Ed N., Lendvai, Nikoletta, Anderson, Larry D., Sutherland, Heather J., DeWall, Stephen, Ellis, Catherine E, He, Zangdong, Mazumdar, Jolly, Wang, Catherine, Opalinska, Joanna B., Voorhees, Peter M.

“…Background Expression of BCMA, a cell surface receptor in the TNF superfamily, is restricted to B cells at later stages of differentiation and is requisite for…”
Get full text

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors by Angevin, Eric, Bauer, Todd M., Ellis, Catherine E., Gan, Hui, Hall, Rigel, Hansen, Aaron, Hoos, Axel, Jewell, Roxanne C., Katz, Jessica, Martin-Liberal, Juan, Maio, Michele, Mayes, Patrick A., Mazumdar, Jolly, Millward, Michael, Rischin, Danny, Schellens, Jan H., Yadavilli, Sapna, Zhou, Helen

“…Background Inducible T cell Co-Stimulator (ICOS), a member of the CD28/B7/CTLA immunoglobulin receptor superfamily, is expressed on T cells after engagement…”
Get full text

Functional characterisation of the human cloned 5‐HT 7 receptor (long form); antagonist profile of SB‐258719 by Thomas, David R., Gittins, Susan A., Collin, Lissa L., Middlemiss, Derek N., Riley, Graham, Hagan, Jim, Gloger, Israel, Ellis, Catherine E., Forbes, Ian T., Brown, Anthony M.

“…The functional profile of the long form of the human cloned 5‐HT 7 receptor (designated h5‐HT 7(a) ) was investigated using a number of 5‐HT receptor agonists…”
Get full text